Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that local injection of minoxidil effectively prevented Ara-C-induced alopecia in newborn rats, while topical application was ineffective.

This study found that new curcumin analogues, such as ASC-J9, can inhibit prostate cancer cell growth by promoting androgen receptor degradation.

Off-label drug use can be risky and requires careful consideration to ensure patient safety.

This study reviews the potential of dibenzo derivatives as safer cancer treatments but finds conflicting evidence about their effectiveness, possibly due to structural differences among the compounds, and reports no new results.

In this study, researchers identified compound 30a as a promising topical androgen receptor antagonist that promoted hair growth in mouse models of androgenetic alopecia without noticeable toxicity, suggesting its potential for treating this hair loss condition.

In this study, aumolertinib improved general health status, functional status, and key symptoms for patients with advanced NSCLC, with an objective response rate of 65.2% and disease control rate of 91.3%, suggesting efficacy and quality of life benefits in first-line treatment.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

This review discusses the use of antiandrogens like flutamide and its derivatives in prostate cancer treatment and highlights the need for next-generation antiandrogens for improved efficacy; it reports no new clinical results.

This study found that using isotretinoin and acitretin was not linked to a higher risk or severity of COVID-19 in patients undergoing systemic retinoid therapy.

In this study using a rabbit model, higher incidences of intraoperative floppy iris syndrome were observed in animals given the α-blocker tamsulosin, suggesting a potential association with increased iris billowing during eye surgery.

This review highlights the potential of amphiregulin as a therapeutic target, noting its role in both fibrotic and malignant diseases, and discusses promising early findings but reports no new clinical results.

This study elucidated the multi-component and multi-target mechanisms by which TR and Am may provide therapeutic benefits for treating androgenetic alopecia.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.

In this animal study, a herbal preparation demonstrated moderate anti-inflammatory and immunomodulating properties, suggesting its potential usefulness for preventing and treating alopecia.

In this retrospective pharmacovigilance study, researchers analyzed over 7,900 adverse event reports related to aromatase inhibitors, identifying common side effects and toxicological mechanisms to highlight potential safety concerns in treating postmenopausal hormone receptor-positive breast cancer.

In this study, all-trans retinoic acid was found to promote differentiation and inhibit proliferation of amelanotic melanocytes from human hair follicles, suggesting a potential role in melanogenesis.

This study found that patients with rheumatoid arthritis taking tofacitinib had higher rates of serious adverse events compared to those with alopecia areata, highlighting the need for careful assessment when using it off-label for alopecia areata.

This review discusses the clinical applications and adverse effects of 5-alpha reductase inhibitors for treating benign prostatic hyperplasia and androgenic alopecia, noting controversies around their implications for other diseases, without reporting new results.

Melatonin may protect inner ear cells from damage by reducing cell death and oxidative stress, potentially treating sudden hearing loss.

This study found that dutasteride reduced β-amyloid plaque load in a cerebral amyloidosis model, seemingly linked to mitochondrial apoptosis and autophagy processes.

In this open-label trial, 9-cis-retinoic acid showed moderate activity against Kaposi sarcoma in AIDS patients, but its use is limited by substantial side effects at higher doses.

This commentary discusses how recent shifts in prostate cancer screening and management may render 5-alpha reductase inhibitors irrelevant for chemoprevention, despite evidence of their long-term safety and effectiveness in preventing low-grade prostate cancer.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

This study found that novel androgen antagonists incorporating a carborane moiety showed anti-androgenic activity comparable to flutamide in a laboratory setting.

This source reports that a network meta-analysis found oral baricitinib and ruxolitinib to be effective and safe for treating alopecia areata, significantly improving response rates over placebos and showing fewer adverse effects than steroid treatments, though precise dosing needs further study.

Alopecia areata is rare in organ transplant patients and may be linked to the drug tacrolimus.

This article reviews the possible therapeutic activities of Angelica gigas Nakai root extracts and their components, noting their potential effects on neuro-cognitive, metabolic, and other health conditions, and reports no new clinical results.

This study found that oral dexamethasone and DPCP were more effective for treating severe alopecia areata compared to oral ritlecitinib and baricitinib, but oral ritlecitinib had better safety outcomes.

Inhibiting certain enzymes made female rats more sensitive to low-level pain.